Neuland Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Neuland Laboratories reported Q1 FY26 standalone revenue from operations of ₹29,275 lakhs, down about 33% from ₹43,960 lakhs in Q1 FY25. Standalone profit after tax fell sharply to ₹1,371 lakhs from ₹9,834 lakhs a year ago, though the prior year quarter included an exceptional gain of ₹2,063 lakhs from the transfer of an investment property in Hyderabad. On a consolidated basis, revenue was ₹29,275 lakhs with PAT of ₹1,390 lakhs and EPS of ₹10.83 (vs ₹76.28 in Q1 FY25). MSKA & Associates issued an unqualified limited review report with no qualifications or emphasis of matter.
The steep year-on-year decline in both revenue and profit is a negative signal, though the Q1 FY25 base was inflated by a one-time property gain. Investors should focus on the underlying operational weakness — revenue and core earnings have contracted meaningfully, which may weigh on the stock in the near term.